Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction

Swedish Orphan Biovitrum AB

www.sobi.com

Latest From Swedish Orphan Biovitrum AB

Bookmark
  • News

Keeping Track: CDER Ties Monthly Novel Approval Record With Nourianz Green Light

By Michael Cipriano

The latest drug development news and highlights from our US FDA Performance Tracker. 

Approvals Drug Review
Bookmark
  • News

AstraZeneca Buys Priority Review Voucher With Two Big Filings On The Horizon

By Jessica Merrill

AstraZeneca paid $95m to Swedish Orphan Biovitrum for the voucher, which it could use to expedite the FDA review of roxadustat or trastuzumab deruxtecan.

Drug Review Launches
Bookmark
  • News

Deal Watch: Aevi Options AstraZeneca Antibody For Rare Disease

By Joseph Haas and Alex Shimmings
Aevi needs to raise funds first, but hopes to develop MEDI2338 for adult-onset Still’s disease. Also, Alnylam plans to leverage Ironwood’s GI expertise for givosiran in acute hepatic porphyria and Ultragenyx snags option to buy GeneTx.
Deals M & A
Bookmark
  • Analysis

Deal Watch: Sanofi Further Opts Out Of CNS Tie-Up With Voyager

By Joseph Haas

Sanofi returns two partnered assets to Voyager, further unraveling 2015 deal. Celgene drops Mereo cancer candidate ahead of merger with Bristol, while Ultragenyx and Arcturus expand their joint rare disease efforts.

Business Strategies Commercial
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Sobi
  • Biovitrum AB
  • Swedish Orphan Biovitrum
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Sweden
  • Parent & Subsidiaries
  • Swedish Orphan Biovitrum AB
  • Senior Management
  • Guido Oelkers, PhD, CEO
    Henrik Stenqvist, CFO
    Milan Zdravkovic, MD, PhD, Head, R&D & CMO
  • Contact Info
  • Swedish Orphan Biovitrum AB
    Phone: (46) 8 697 20 00
    Tomtebodavägen 23A
    Stockholm, SE-112 76
    Sweden
Advertisement
Advertisement
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By